Page last updated: 2024-12-08

nicotinamide-beta-riboside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-ribosylnicotinamide : A pyridine nucleoside consisting of nicotinamide with a beta-D-ribofuranosyl moiety at the 1-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439924
CHEMBL ID438497
CHEBI ID15927
SCHEMBL ID938611
MeSH IDM0070321

Synonyms (43)

Synonym
beta-nicotinamide d-riboside
CHEBI:15927 ,
3-carbamoyl-1-beta-d-ribofuranosylpyridinium
srt647
pyridinium, 3-(aminocarbonyl)-1-beta-d-ribofuranosyl-
srt 647
srt-647
truniagen
niagen
1-(beta-d-ribofuranosyl)nicotinamide
1341-23-7
n-ribosylnicotinamide
nicotinamide riboside
1-(beta-d ribofuranosyl)nicotinamide
nicotinamide-beta-riboside
C03150
nicotinamide ribonucleoside
ribosylnicotinamide
nicotinamide ribose
n-ribosyl-nicotinamide
CHEMBL438497
1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide
unii-0i8h2m0l7n
0i8h2m0l7n ,
AM84366
SCHEMBL938611
3-carbamoyl-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-ium
3-carbamoyl-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1$l^{5}-pyridin-1-ylium
nicotinamide riboside [who-dd]
pyridinium, 3-(aminocarbonyl)-1-.beta.-d-ribofuranosyl-
1-beta-delta-ribosyl-3-pyridinecarboxamide
1-beta-d-ribosyl-3-pyridinecarboxamide
3-(aminocarbonyl)-1-beta-d-ribofuranosyl-pyridinium
3-(aminocarbonyl)-1-beta-delta-ribofuranosyl-pyridinium
1-b-d-ribosyl-3-pyridinecarboxamide
3-(aminocarbonyl)-1-beta-d-ribofuranosylpyridinium
Q3334152
DB14933
HY-123033
CS-0080934
DTXSID501010039
beta-nicotinamide ribose;beta-nicotinamide riboside
AKOS040740858

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No serious adverse events due to NR supplementation were observed and safety blood tests were normal."( A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Brenner, C; Christensen, B; Dollerup, OL; Jessen, N; Møller, N; Ringgaard, S; Schmidt, MS; Stødkilde-Jørgensen, H; Sulek, K; Svart, M; Treebak, JT, 2018
)
0.48
" In contrast to a previously published safety assessment using a different synthetic NR (NIAGEN), whose no-observed-adverse-effect-level (NOAEL) was reported to be 300 mg/kg/d, there were no adverse changes in clinical pathology parameters and no notable macroscopic or microscopic findings or treatment-related effects at similar doses."( Safety Assessment of High-Purity, Synthetic Nicotinamide Riboside (NR-E) in a 90-Day Repeated Dose Oral Toxicity Study, With a 28-Day Recovery Arm.
Chen, J; Dellinger, RW; Guarente, L; Holmes, HE; Marinescu, AG; Mendes, O; Morris, M,
)
0.13
" The primary outcome was safety, defined as the frequency of moderate and severe adverse events."( NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.
Af Geijerstam, SA; Berven, H; Dölle, C; Haugarvoll, K; Kverneng, S; Sheard, E; Skeie, GO; Søgnen, M; Tzoulis, C, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" These findings establish bioavailability and potent effects of these nucleosides in stimulating the increase of NAD+ concentrations in mammalian cells."( Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells.
Chan, NY; Sauve, AA; Yang, T, 2007
)
0.34
" Additional studies with nicotinamide riboside in models of Alzheimer's disease indicate bioavailability to brain and protective effects, likely by stimulation of brain NAD synthesis."( Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection.
Chi, Y; Sauve, AA, 2013
)
0.39
" Due to its beneficial effects and to the evidence of the reduction of NAD bioavailability with aging, researchers are seeking ways to replenish the cellular NAD pool, by administrating its precursors (NAM and NR), believing that it will reduce the RGC vulnerability to external stressors, such as increased IOP."( The use of Nicotinamide and Nicotinamide riboside as an adjunct therapy in the treatment of glaucoma.
Costa, VP; Goulart Nacácio E Silva, S; Occhiutto, ML, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" NRPT dosing was increased in each Step: Step 1250/50 mg, Step 2500/100 mg, Step 3750/150 mg and Step 41,000/200 mg."( Nicotinamide riboside with pterostilbene (NRPT) increases NAD
Dellinger, R; Guarente, LP; Parikh, SM; Rhee, EP; Simic, P; Vela Parada, XF, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
N-glycosylnicotinamide
pyridine nucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (31)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of vitamins and cofactors146155
Metabolism of water-soluble vitamins and cofactors102114
Nicotinate metabolism2243
Biological oxidations150276
Phase I - Functionalization of compounds69175
Nicotinate and Nicotinamide Metabolism1434
NAD Salvage620
NAD Metabolism1435
Nicotinate and Nicotinamide metabolism ( Nicotinate and Nicotinamide metabolism )2225
N-Ribosyl-nicotinamide + Orthophosphate = Nicotinamide + D-Ribose 1-phosphate ( Nicotinate and Nicotinamide metabolism )13
Disease1278231
Infectious disease89579
pyridine nucleotide cycling (plants)322
Leishmania infection6626
Cell recruitment (pro-inflammatory response)187
Purinergic signaling in leishmaniasis infection187
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
Parasitic Infection Pathways6626
pyridine nucleotide cycling (plants)022
NAD salvage pathway IV (from nicotinamide riboside)88
superpathway of NAD biosynthesis in eukaryotes1135
NAD salvage pathway III (to nicotinamide riboside)213
nicotinamide riboside salvage pathway II15
nicotinamide riboside salvage pathway I37
nicotinamide riboside salvage pathway06
NAD salvage pathway II011
NAD salvage pathway III07
NAD metabolism, sirtuins and aging03
NAD+ metabolism014
NAD+ biosynthetic pathways014

Bioassays (6)

Assay IDTitleYearJournalArticle
AID304769Increase in NAD+ concentration in HEK293 cells at 1 mM after 24 hrs by isotope-dilution technique relative to control2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells.
AID304768Increase in NAD+ concentration in mouse AB1 cells at 1 mM after 24 hrs by isotope-dilution technique relative to control2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells.
AID304784Cell viability in HEK293 cells at 750 uM after 48 hrs by MTT assay relative to control2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells.
AID304770Increase in NAD+ concentration in mouse Neuro 2a cells at 1 mM after 24 hrs by isotope-dilution technique relative to control2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells.
AID304785Cell viability in mouse Neuro 2a cells at 750 uM after 48 hrs by MTT assay relative to control2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells.
AID304783Cell viability in mouse AB1 cells at 750 uM after 48 hrs by MTT assay relative to control2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (220)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (5.00)18.7374
1990's7 (3.18)18.2507
2000's25 (11.36)29.6817
2010's76 (34.55)24.3611
2020's101 (45.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.90 (24.57)
Research Supply Index5.50 (2.92)
Research Growth Index5.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (8.97%)5.53%
Reviews25 (11.21%)6.00%
Case Studies1 (0.45%)4.05%
Observational0 (0.00%)0.25%
Other177 (79.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]